The overall goal of this specimen procurement core is the collection, maintenance, and distribution of high quality biologic samples from a spectrum of prostate cancer and control patients, along with collection of accurate linked clinical and pathologic data on these samples. The Robert H. Lurie Comprehensive Cancer Center's Specialized Program of Research Excellence (SPORE) in prostate cancer consists of three prostate cancer treatment centers;Northwestern Memorial Hospital (NMH), Evanston Northwestern Healthcare (ENH; principally Evanston Hospital), and the Jesse Brown Veterans Administration Medical Center (VA). The University of Chicago is now integrated into our SPORE, and in the future will contribute biologic samples as well. Because these institutions see large numbers of new prostate cancer patients from a spectrum of socioeconomic and ethnic groups, with over 500 annual radical prostate ctomies performed, our access to patient derived tissues for research is high and diverse. NMH, the VA, and ENH have successfully implemented sample procurement to support the prostate SPORE efforts and collectively, these facilities have procured samples on approximately 1900 patients since 2001. Samples (tissue, serum, DNA, RNA, and TMAs) and data have been provided for 48 studies to date. The Robert H. Lurie C omprehensive Cancer Center Pathology Core Facility (RHLCCC-PCF), a shared resource of the RHLCCC, is independent of but complements the tissue procurement by providing research histology expertise. This core will continue the collection of fixed embedded and fresh frozen tissues, urine, blood and blood components, as well as the acquisition and database storage of essential pathologic and clinical information needed for conducting translational research. Additionally, the facility has constructed numerous tissue microarrays to suit the needs of SPORE investigators. This resource will benefit not only our SPORE investigators, but will facilitate research activities of scientists within and outside the parent institution. T his process is supervised by a Sample Review and Disbursement Committee, (including physicians, pathologists and a patient advocate), the SPORE Executive Committee, and reviewed by the individual Institutional Review Boards (IRBs) on an annual basis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586
Hung, Michelle E; Leonard, Joshua N (2016) A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles 5:31027
Nyame, Yaw A; Murphy, Adam B; Bowen, Diana K et al. (2016) Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol 34:1345-9
Anderson, Blake B; Oberlin, Daniel T; Razmaria, Aria A et al. (2016) Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol :
Kregel, Steven; Chen, James L; Tom, Westin et al. (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7:26259-74
Ye, Cong; Geng, Zhe; Dominguez, Donye et al. (2016) Targeting Ornithine Decarboxylase by ?-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol 196:915-23
Jin, Hong-Jian; Jung, Segun; DebRoy, Auditi R et al. (2016) Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Oncotarget 7:54616-54626

Showing the most recent 10 out of 201 publications